Gyre Therapeutics, Inc. (GYRE)
6.72
+0.03
(+0.45%)
USD |
NASDAQ |
Sep 16, 13:45
Gyre Therapeutics Debt to Equity Ratio : 0.0262 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0262 |
| March 31, 2026 | 0.0081 |
| December 31, 2025 | 0.0089 |
| September 30, 2025 | 0.0114 |
| June 30, 2025 | 0.0151 |
| March 31, 2025 | 0.0233 |
| December 31, 2024 | 0.0252 |
| September 30, 2024 | 0.0284 |
| June 30, 2024 | 0.0324 |
| March 31, 2024 | 0.0049 |
| December 31, 2023 | 0.0084 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.6185 |
| December 31, 2022 | 0.0144 |
| September 30, 2022 | 0.013 |
| June 30, 2022 | 0.0179 |
| March 31, 2022 | 0.0705 |
| December 31, 2021 | 0.058 |
| September 30, 2021 | 0.0394 |
| June 30, 2021 | 0.0337 |
| March 31, 2021 | 0.0143 |
| December 31, 2020 | 0.0216 |
| September 30, 2020 | 0.0154 |
| June 30, 2020 | 0.0144 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0173 |
| December 31, 2019 | 0.0264 |
| September 30, 2019 | 0.0236 |
| June 30, 2019 | 0.0218 |
| March 31, 2019 | 0.0202 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.1652 |
| September 30, 2017 | 0.2206 |
| June 30, 2017 | 0.1901 |
| March 31, 2017 | 0.9144 |
| December 31, 2016 | 1.207 |
| September 30, 2016 | 1.513 |
| June 30, 2016 | 1.292 |
| March 31, 2016 | 1.105 |
| December 31, 2015 | 1.074 |
| September 30, 2015 | 0.9605 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.0042 |
| June 30, 2014 | 0.006 |
| March 31, 2014 | 0.0074 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Cytokinetics, Inc. | -7.324 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 199.26M |
| Total Liabilities (Quarterly) | 33.51M |
| Shareholders Equity (Quarterly) | 130.36M |
| Current Ratio | 4.259 |
| Net Debt Paydown Yield | -0.05% |